Overview
A structured, short-term clinical framework designed to reduce acute inflammatory signaling, control pain amplification, and accelerate early tissue repair following injury or procedural inflammation. This protocol combines local tissue-support peptides with systemic anti-inflammatory modulators and, when indicated, mitochondrial support to prevent inflammation chronification. The objective is to transition patients efficiently from the acute inflammatory phase into functional recovery while maintaining defined cycling and monitoring parameters.
Clinical Targets
| Acute musculoskeletal injury (sprain, strain, contusion) |
| Post-procedural inflammation |
| Sports trauma and overuse flare-ups |
| Localized soft tissue swelling and tenderness |
Expected Outcomes
| Reduction in inflammatory pain (VAS improvement) |
| Decreased swelling and localized tenderness |
| Improved range of motion |
| Accelerated transition to proliferative healing phase |
| Reduced risk of inflammation chronification |
Core Stack
BPC-157
| Administration Route: Subcutaneous (SubQ), perilesional |
| Dose: 250–500 mcg |
| Frequency: Twice daily |
| Duration: 4–6 weeks |
KPV
| Administration Route: SubQ or Oral |
| Dose: 200–500 mcg |
| Frequency: 1–2 times daily |
| Duration: 4–6 weeks |
Selank
| Administration Route: Intranasal |
| Dose: 200–400 mcg |
| Frequency: Twice daily |
| Duration: 2–4 weeks |
Enhanced Stack (if indicated)
TB-500 (Thymosin β4)
| Administration Route: SubQ |
| Dose: 750 mcg–1.5 mg |
| Frequency: Twice weekly (Weeks 1–2), then weekly |
| Duration: 6–8 weeks |
SS-31 (Elamipretide)
| Administration Route: SubQ |
| Dose: 0.5–1.0 mg |
| Frequency: Daily |
| Duration: 4 weeks |
Phase Structure
Phase 1: Loading (Weeks 1–2)
| BPC-157: 500 mcg SubQ, twice daily |
| KPV: 500 mcg, twice daily |
| Selank: Twice daily |
| TB-500: Twice weekly (if indicated) |
| SS-31: Daily (if indicated) |
Phase 2: Active Recovery (Weeks 3–4)
| BPC-157: 250–500 mcg, twice daily |
| KPV: 1–2 times daily |
| TB-500: Weekly (if used) |
| Weekly reassessment of pain and mobility |
Phase 3: Taper (Weeks 5–6)
| Reduce BPC-157 to once daily, then discontinue |
| Taper KPV |
| Discontinue Selank |
| Continue TB-500 only if repair incomplete |
Rationale
This protocol integrates localized angiogenic signaling with systemic inflammatory modulation. BPC-157 functions as the anchor peptide for tissue repair and nitric oxide support. KPV provides direct NF-κB pathway modulation. Selank reduces central sensitization and anxiety-amplified pain signaling. When required, TB-500 enhances cellular migration, and SS-31 stabilizes mitochondrial membranes to reduce oxidative stress propagation.
Monitoring
| Weekly VAS pain scale |
| Range of motion assessment |
| Swelling and tenderness tracking |
| Functional tolerance evaluation |
Cycling Guidelines
| BPC-157: 4–6 weeks typical for acute cases |
| KPV: 4–6 weeks typical |
| Selank: 2–4 weeks typical |
| TB-500: 6–8 weeks typical |
| SS-31: 4 weeks typical |
Contraindications
| Pregnancy or breastfeeding |
| Active malignancy |
| Active systemic infection |
| Severe hepatic or renal impairment |
| Known hypersensitivity to components |
Mathematical Calculation Tool
The calculator below allows mathematical concentration and volume calculations using variable vial strengths and reconstitution volumes. This tool is provided strictly for arithmetic reference.
Peptide Reconstitution Calculator
For Educational & Professional Reference Only
Clinical Disclaimer
This protocol is provided for educational and informational purposes for licensed healthcare professionals. These compounds and protocols are not intended to diagnose, treat, cure, or prevent any disease. Patient-specific medical evaluation and clinical judgment are required prior to implementation.